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Reference intervals for urinary renal injury 
biomarkers KIM‑1 and NGAL in healthy 
children
Aim: The aim of this study was to establish reference intervals in healthy children 
for two novel urinary biomarkers of acute kidney injury, kidney injury molecule‑1 
(KIM‑1) and neutrophil gelatinase‑associated lipocalin (NGAL). Materials & Methods: 
Urinary biomarkers were determined in samples from children in the UK (n = 120) 
and the USA (n = 171) using both Meso Scale Discovery (MSD) and Luminex‑based 
analytical approaches. Results: 95% reference intervals for each biomarker in each 
cohort are presented and stratified by sex or ethnicity where necessary, and age‑
related variability is explored using quantile regression. We identified consistently 
higher NGAL concentrations in females than males (p < 0.0001), and lower KIM‑1 
concentrations in African–Americans than Caucasians (p = 0.02). KIM‑1 demonstrated 
diurnal variation, with higher concentrations in the morning (p < 0.001). Conclusion: 
This is the first report of reference intervals for KIM‑1 and NGAL using two analytical 
methods in a healthy pediatric population in both UK and US‑based populations. 
Keywords: KIM‑1 • nephrotoxicity • pediatric nephrology • proximal tubule 
Clinical definitions of acute kidney injury 
(AKI) rely on elevations in serum creatinine 
(sCr) [1–3], which is delayed in response to 
renal injury [4]. Therefore, diagnosis of AKI 
is frequently late and the degree of damage 
may be underestimated [5]. sCr is a marker of 
glomerular filtration and therefore not spe-
cific to damage in other parts of the neph-
ron. Interpretation of sCr values in children 
is made more difficult by variation in the 
production of creatinine which depends on 
age, sex and weight (in particular, muscle 
mass). Furthermore, sCr values in the new-
born serum initially reflect maternal values. 
For these reasons, there has been increasing 
interest in the development of novel urinary 
biomarkers such as kidney injury molecule- 1 
(Kim-1 in rodents; KIM-1 in man) and 
neutrophil gelatinase-associated lipo calin 
(NGAL). KIM-1 has been qualified by reg-
ulatory authorities to support preclinical 
drug safety evaluation [6]. These biomarkers 
are not only more sensitive than sCr for the 
identification of AKI but can also indicate 
specific damage to the proximal tubular 
region of the nephron [7,8]. Additionally, the 
ability to assay the markers noninvasively in 
urine represents a significant advantage over 
current methods, especially for the pediatric 
population.
We recently demonstrated the feasibility of 
measuring urinary KIM-1 and NGAL, and 
their quantitative relationship to aminogly-
coside-induced nephrotoxicity in neonates 
[9]. However, a comprehensive understand-
ing of changes in these biomarkers in urine 
is critical in order to define reference values 
in healthy populations to allow appropriate 
interpretation of novel clinical and transla-
tional data, and support their ongoing clin-
ical qualification. Historically many pedi-
atric reference intervals have been extrap-
olated from adult reference data. However, 
this is not appropriate when one considers 
the course of renal maturation and other 
develop mental changes during childhood 
[10]. The aim of this study was to determine 
the urinary reference intervals for KIM-1 
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and NGAL in healthy children from both the UK and 
USA, and to assess the impact of factors including age, 
sex, ethnicity, time of day and analytical platform. 
Patients & methods
Patient recruitment & sample collection
We recruited healthy children aged from birth to 
16 years in Liverpool (UK) between April 2012 and 
February 2013. Eligible children were recruited at a 
number of sites, including a nursery, primary school, 
secondary school and elective minor surgery admis-
sions wards at Alder Hey Children’s Hospital (Liver-
pool, UK). We also recruited children of staff mem-
bers at Alder Hey Children’s Hospital. Children were 
excluded if they had a current febrile illness, any 
history of kidney problems or urinary tract infec-
tions, were taking medications known to cause renal 
problems (especially NSAIDs such as ibuprofen), had 
a diagnosis of cystic fibrosis (by sweat test or geno-
type), or had a history of exposure to aminoglycoside 
antibiotics within the last 3 months. (We specifically 
excluded children with cystic fibrosis or a history of 
exposure to aminoglycoside antibiotics as we aim to 
investigate the utility of urinary biomarkers in these 
patients in another study, and will use this group as 
a comparison). The DERIVE study received ethical 
approval from the National Research Ethics Service 
(NRES) Committee Northwest – Liverpool East, UK. 
It was registered on the UK Clinical Research Net-
work portfolio (UKCRN 11810) and received support 
from the Medicines for Children Research Network 
(MCRN) and the Primary Care Research Network 
(PCRN). The study was conducted in accordance 
with the  Declaration of Helsinki.
Informed written consent was obtained from car-
ers or guardians on the behalf of the minors/chil-
dren involved in our study. Those participants aged 
16 years were able to consent for themselves. Consent 
was obtained from all children to provide one urine 
sample. In schools each participating child produced 
a urine sample during the school day, which was col-
lected by the research team. For children attending 
the nursery and children of staff at Alder Hey Chil-
dren’s Hospital, parents were asked to collect a morn-
ing urine sample at home and bring the sample in to 
the research team at the site of recruitment on the 
day of collection. Children recruited on the surgical 
admissions wards produced a urine sample before 
their planned surgical procedure.
In addition, some children consented to provide four 
further urine samples (three morning urine samples at 
1-week intervals following their initial urine sample, 
and one bedtime urine sample collected the evening 
before one of the morning urine samples). Morning 
samples were the first micturition of the day, and the 
evening samples were collected just before the child 
went to bed and kept in the home refrigerator over-
night. Parents were given sample pots to take home to 
collect these samples. All samples were brought on the 
morning of collection to the site of recruitment.
Urine samples were collected from each child by 
an appropriate method dependent on the age of the 
child. The normally preferred method was a clean 
catch urine sample into a sterile container. Samples 
were transferred to (if not already collected in) a sterile 
container and then centrifuged at 2000 × g for 4 min. 
Supernatant was aliquoted and then stored at -80°C.
Healthy pediatric subjects were recruited at Chil-
dren’s Mercy Hospitals and Clinics (MO, USA) 
to participate in a longitudinal study investigating 
changes in drug metabolism activity, specifically 
CYP2D6 and CYP3A4 activities, through puberty 
using dextromethorphan as a probe. Children of both 
genders were eligible if they were between the ages 
of 7 and 16 years; a subset of the study population 
was diagnosed with attention deficit and hyperac-
tivity disorder (ADHD) or attention deficit disorder 
(ADD), and the remainder were non-ADHD/ADD 
controls. Exclusion criteria included: i) current ther-
apy with medications metabolized by or known to 
inhibit CYP2D6; ii) existing asthma or other respira-
tory diseases associated with hypercapnia; iii) history 
of metabolic disease, gastroesophageal reflux disease 
or gastrointestinal disorders; iv) demonstrated adverse 
reaction to previous dextromethorphan exposure; 
v) impaired hepatic activity as determined by routine 
liver function tests and physical exam; vi) pregnancy; 
vii) BMI less than 5th percentile. 
Subjects were given a complete medical examina-
tion, including assessment of Tanner stage, and blood 
samples were taken for liver function testing and DNA 
collection at the screening visit. The parent study 
entitled ‘Exogenous and Endogenous Biomarkers of 
CYP2D6’ and secondary use of the residual urine was 
approved by the University of Missouri–Kansas City 
Health Sciences Pediatric Institutional Review Board. 
The parent study is also registered as registered as 
trial NCT01118858 at ClinicalTrials.gov. The study 
was conducted in  accordance with the Declaration of 
 Helsinki.
Subjects were recruited by Children’s Mercy Hospi-
tal Clinical Pharmacology staff, and parents and chil-
dren were given verbal and written information about 
the study. If subjects agreed to participate in the study, 
a screening questionnaire was completed with the par-
ents; written informed permission was obtained from 
the subject’s parents and assent was obtained from 
 children >7 years of age. 
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Pediatric subjects were instructed to fast overnight 
and report to the Children’s Mercy Hospitals and 
Clinics the following morning for dextromethorphan 
phenotyping. Subjects were given a single oral dose of 
dextromethorphan (0.5 mg/kg as Robitussin Cough 
Syrup, Pfizer, Inc., NY, USA). Urine was collected 
predose and for 4 h following dosing by clean catch 
into sterile containers. At the end of the 4-h collection 
period, subjects were instructed to void their bladder. 
All urine collected during the 4-h collection interval 
was kept at 4°C until completion of the collection 
period, pooled, mixed, dispensed into multiple ali-
quots of various volumes, frozen and stored at -80°C. 
Unthawed aliquots of 4-h urine samples were shipped 
on dry ice to the University of Liverpool where they 
were stored at -80°C until ana lysis. The 171 samples 
included in this study represent the first of seven study 
visits at 6-month intervals for 3 years.
Determination of urinary biomarkers
Collected urine samples were thawed, mixed and 
centrifuged (3000 rpm, 5 min). Biomarker measure-
ments were performed on the resulting supernatants. 
Urinary KIM-1 and NGAL were measured using elec-
trochemiluminescent assays (Meso Scale Discovery 
[MSD], MD, USA). The MSD assays are sandwich 
immunoassays run on 96-well plates precoated with 
either a KIM-1- or NGAL-specific capture antibody, 
and utilize a detection antibody conjugated to an 
electrochemiluminescent label. The assays were run 
according to the manufacturer’s protocol, with a turn-
around of 6 h. For KIM-1 the upper (ULOQ) and 
lower limits of quantitation (LLOQ) on a seven- point 
calibration curve were 5000 and 1.22 pg/ml, respec-
tively. Intra- and inter-assay precision were <6 and 
<7%, respectively, on three plates on different occa-
sions, recovery of spiked samples was 104–107%, and 
dilutional linearity was shown at 1 in 10, 1 in 100 and 
1 in 1000 dilutions in the assay diluent. For NGAL the 
ULOQ and LLOQ on a seven-point calibration curve 
were 10,000 and 40.96 pg/ml, respectively. Intra- and 
inter-assay precision were <15 and <13%, respectively, 
on three plates on different occasions, recovery of 
spiked samples was 94–108%, and dilutional linearity 
was shown at 1 in 10, 1 in 100 and 1 in 1000 dilu-
tions in the assay diluent. For both assays the lower 
limit of quantitation is greater than 2 standard devia-
tions above the background value (diluent alone), and 
therefore the LLOQ is taken as the limit of detection. 
Urine samples were run in duplicate at a dilution of 
1 in 10 in MSD Diluent 37, and repeated at a dilution 
of 1 in 100 if they remained too concentrated. 
Urinary KIM-1 and NGAL measurements were also 
performed using microsphere-based Luminex tech-
nology, as previously validated and described, with 
a turnaround time of 4–6 h [9,11]. Biomarker values 
were normalized to urinary creatinine (uCr), which 
was determined spectrophotometically, as previously 
described [12]. Laboratory ana lysis was blinded to 
 participants’ clinical characteristics.
Statistical ana lysis
Biomarker concentrations from the baseline urine sam-
ple produced by each participant were used to calcu-
late the overall reference intervals following approaches 
recommended for pediatric reference intervals [13], 
using SAS version 9.3 (SAS Institute, NC, USA) and R 
[14]. The distributions of KIM-1 and NGAL followed a 
near Log normal distribution. Therefore, a logarithmic 
transformation was applied to the biomarker values in 
order to approximate a Gaussian distribution, allowing 
a parametric approach to ana lysis. Biomarker levels in 
the two reference populations were compared using 
an independent samples t-test. Reference ranges were 
then calculated in the two cohorts separately. The US 
cohort included both patients with ADHD/ADD and 
healthy controls. Although medications licensed for 
the management of ADHD/ADD do not commonly 
have nephrotoxic effects, we cannot exclude the possi-
bility of rare adverse effects. An independent samples 
t-test was used to compare these groups. There were 
no differences identified between these two groups for 
KIM-1 or NGAL, and therefore the two groups were 
analyzed together.
Outliers were identified and removed according to 
Tukey’s method [15]. We assessed the need for partition-
ing of the reference population by the binary factors 
sex and ethnicity using independent samples t-tests. 
In order to assess whether reference ranges varied sig-
nificantly with age, we used the method of quantile 
regression [16], with age as the independent variable. 
Quantile regression was applied either on the complete 
dataset, or on the dataset partitioned by sex and/or 
ethnicity depending on which factors were found to be 
statistically significant in the t-tests. Where quantiles 
were not found to significantly vary with age (p ≥ 0.05 
in the quantile regression model), the 2.5th and 97.5th 
quantiles were referred to in order to calculate the 95% 
reference intervals for each biomarker. We also report 
90% CIs for the upper limit of the reference interval 
[13,17]. Where quantiles were found to significantly vary 
with age (p < 0.05), we report the predicted values for 
the 2.5th and 97.5th quantiles, as obtained from the 
fitted quantile regression model, for particular age 
groups, together with 90% CIs for the upper limit.
Differences between morning and evening paired 
biomarker values were assessed using a paired t-test. 
Within-subject variation over up to four morning 
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urine samples is measured using mean standard devi-
ation (SD). Reference intervals for urinary creatinine 
were also calculated using the same statistical approach 
as for KIM-1 and NGAL. Differences between the 
MSD and Luminex methods of biomarker ana lysis 
were assessed using a regression  ana lysis  according to 
the method of Bland and Altman [18].
Results 
A total of 120 healthy children (64 male and 56 
female) recruited in the UK provided at least one 
urine sample as part of the study. The mean age was 
9.05 years (standard deviation [SD]: 4.41), and 39 
participants provided more than one sample. In par-
allel, one urine sample was collected from 171 healthy 
children (108 male and 63 female) recruited in the 
USA. This cohort had a narrower age range (mean 
age: 11.20 years; SD: 2.49) than the UK cohort and 
was more ethnically diverse. While we set out to 
recruit from birth to 16 years of age in the UK cohort, 
in practice only one child under 1 year of age was suc-
cessfully recruited, and we have therefore presented 
reference intervals for children aged 1 year and above. 
In the US cohort 65 out of 171 (38%) were patients 
with ADHD/ADD, and the remainder were con-
trols. There were no differences identified between 
these two groups for KIM-1 or NGAL, suggesting 
there is not a significant effect of the diagnosis or of 
medication exposure on the urinary concentrations 
of these biomarkers. Table 1 summarizes volunteer 
demographics for the two cohorts separately.
Reference intervals for each biomarker were deter-
mined in both cohorts. For the UK cohort, partic-
ipants with non-Caucasian ethnicity (n = 12) were 
excluded from the calculation of reference ranges, 
and we were therefore unable to consider the effect 
of ethnicity in this cohort. For the US cohort, partic-
ipants with ethnicity other than Caucasian or Afri-
can–American (n = 15) were excluded. The reference 
intervals are presented in Table 2, stratified by ethnic-
ity and/or sex as appropriate, and then by age. The 
predicted quantile values reported reflect the value for 
the middle age within each age group.
Using MSD, there was a significant difference 
(p < 0.001) in the mean urinary KIM-1 concentration 
between the two cohorts (UK [MSD]: 0.43 ng/mg Cr, 
95% CI: 0.37–0.50 ng/mg Cr; US [MSD]: 0.18 ng/
mg Cr, 95% CI: 0.16–0.20 ng/mg Cr). However, 
there was no difference between the mean NGAL con-
centrations (UK [MSD]: 10.71 ng/mg Cr, 95% CI: 
8.76–13.11 ng/mg Cr; US (MSD): 8.19 ng/mg Cr, 
95% CI: 6.80–9.86 ng/mg Cr). 
Within both cohorts, urinary KIM-1 concentra-
tions were not significantly associated with sex. How-
ever, we consistently identified a significant difference 
(p < 0.0001) in mean NGAL concentration between 
males and females in both cohorts (UK males 
[MSD]: 6.55 ng/mg Cr, 95% CI: 5.16–8.32 ng/mg 
Cr; UK females [MSD]: 19.18 ng/mg Cr, 95% CI: 
14.63–25.14 ng/mg Cr; US males [MSD]: 3.95 ng/mg 
Cr, 95% CI: 3.53–4.42 ng/mg Cr; US females [MSD]: 
28.56 ng/mg Cr, 95% CI: 22.09–36.93 ng/mg Cr). 
The US cohort was more ethnically diverse, with 
77 subjects of African–American descent, 79 Cauca-
sians and 15 of dual heritage (although these 15 were 
excluded from the ana lysis). Mean NGAL concentra-
tions were not significantly associated with ethnic-
ity. However, for KIM-1 a significant difference was 
found between Caucasian and African–American 
ethnic groups (Caucasians [MSD]: 0.21 ng/mg Cr, 
95% CI: 0.17–0.26 ng/mg Cr; African–Americans 
[MSD]: 0.16 ng/mg Cr, 95% CI: 0.13–0.18 ng/mg 
Cr; p = 0.02).
Using MSD, we assessed intraindividual variability 
in the UK cohort in 39 individuals who provided one 
morning sample each week for up to 4 weeks. KIM-1 
Table 1. Demographic characteristics of UK and US cohorts.
Cohort demographics UK cohort US cohort
Number in cohort 120 171
Males:females (n) 64:56 108:63
Age 0–4 years (n) 27
Age 5–8 years (n) 32 38
Age 9–12 years (n) 32 85
Age 13–16 years (n) 29 48
Caucasian (n) 108 79
African–American (n) 77
Other ethnicity (n) 12 15
The US cohort contained children aged 7–16 years only.
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Table 2. Biomarker reference intervals by quantile regression. 
Cohort and 
biomarker
2.5th quantile (90% CI), 
ng/mg Cr
50th quantile (90% CI), 
ng/mg Cr
97.5th quantile (90% CI), 
ng/mg Cr
CI:RI 
ratio
UK KIM‑1 (MSD) Caucasians, male and female (n = 107)
Age 1–4 years 0.08 (0.03–0.12) 0.46 (0.38–0.57) 2.39 (1.96–2.91) 0.41
Age 5–8 years 0.08 (0.03–0.12) 0.46 (0.38–0.57) 1.84 (1.62–2.10) 0.27
Age 9–12 years 0.08 (0.03–0.12) 0.46 (0.38–0.57) 1.42 (1.22–1.65) 0.32
Age 13–16 years 0.08 (0.03–0.12) 0.46 (0.38–0.57) 1.10 (0.87–1.39) 0.51
UK NGAL (MSD) Caucasians, females (n = 48)
Age 1–4 years 8.34 (3.14–22.15) 10.49 (8.02–13.72) 128.84 (54.03–307.25) 2.10
Age 5–8 years 3.84 (2.64–5.60) 15.30 (12.78–18.32) 143.95 (81.17–255.29) 1.24
Age 9–12 years 1.77 (0.95–3.31) 22.31 (16.79–29.66) 160.83 (104.23–248.19) 0.91
Age 13–16 years 0.82 (0.22–3.01) 32.55 (20.41–51.90) 179.70 (100.73–320.58) 1.23
UK NGAL (MSD) Caucasians, males (n = 58)
Age 1–16 years 1.33 (0–1.89) 5.21 (4.66–6.49) 64.59 (29.14–Inf)† Inf
UK KIM‑1 (Luminex) Caucasians, male and female (n = 108)
Age 1–16 years 0.03 (0.002–0.04) 0.17 (0.15–0.18) 0.63 (0.49–Inf)† Inf
UK NGAL (Luminex) Caucasians, females (n = 50)
Age 1–4 years 1.25 (0.11–14.06) 63.43 (38.09–83.93) 706.72 (247.84–2015.28) 2.51
Age 5–8 years 2.72 (0.92–8.06) 63.43 (38.09–83.93) 581.69 (297.53–1137.25) 1.45
Age 9–12 years 5.95 (2.41–14.70) 63.43 (38.09–83.93) 478.78 (327.30–700.38) 0.79
Age 13–16 years 13.00 (1.46–116.09) 63.43 (38.09–83.93) 394.08 (256.72–604.94) 0.91
UK NGAL (Luminex) Caucasians, males (n = 58)
Age 1–4 years 0.36 (0–0.58) 6.30 (4.53–10.18) 229.90 (118.14–447.38) 1.43
Age 5–8 years 0.36 (0–0.58) 6.30 (4.53–10.18) 180.51 (114.13–285.51) 0.95
Age 9–12 years 0.36 (0–0.58) 6.30 (4.53–10.18) 141.73 (103.94–193.27) 0.63
Age 13–16 years 0.36 (0–0.58) 6.30 (4.53–10.18) 111.28 (80.96–152.95) 0.65
US KIM‑1 (MSD) Caucasians, male and female (n = 73)
Age 7–8 years 0.014 (0.007–0.032) 0.23 (0.19–0.29) 0.79 (0.62–Inf)† Inf
Age 9–12 years 0.031 (0.022–0.044) 0.23 (0.19–0.29) 0.79 (0.62–Inf)† Inf
Age 13–16 years 0.088 (0.051–0.151) 0.23 (0.19–0.29) 0.79 (0.62–Inf)† Inf
US KIM‑1 (MSD) African–American, male and female (n = 65)
Age 7–8 years 0.038 (0.018–0.077) 0.17 (0.13–0.19) 0.42 (0.34–Inf)† Inf
Age 9–12 years 0.048 (0.035–0.066) 0.17 (0.13–0.19) 0.42 (0.34–Inf)† Inf
Age 13–16 years 0.067 (0.043–0.106) 0.17 (0.13–0.19) 0.42 (0.34–Inf)† Inf
US NGAL (MSD), females (n = 55)
Age 7–8 years 1.30 (0–4.07) 19.30 (12.36–30.14) 58.26 (42.06–80.70) 0.68
Age 9–12 years 1.30 (0–4.07) 35.38 (28.40–44.09) 96.95 (82.72–113.64) 0.32
Age 13–16 years 1.30 (0–4.07) 79.40 (49.91–126.32) 191.21 (137.58–265.74) 0.67
95% RIs (2.5th and 97.5th quantiles) along with median values (50th quantile) and their 90% CIs were estimated using quantile regression 
methodology. RIs are reported by cohort (UK or USA), biomarker (KIM‑1 or NGAL) and analytical method (MSD or Luminex). Where 
biomarker concentrations were significantly associated with sex or ethnicity (p < 0.05), RIs are presented by these partitions. We report 
quantile values for the middle age within each age group. A ratio of the 90% CI for the 97.5th quantile to the 95% RI (CI:RI ratio) is given. 
The US Cohort contained children aged 7–16 years only.  
†For RIs where there was no significant association with age, it was not possible to calculate upper limits for the CIs due to small sample size 
and the extreme percentile. 
CI: Confidence interval; Cr: Creatinine; Inf: Infinity; MSD: Meso Scale Discovery; RI: Reference interval.
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was less variable within individuals than NGAL 
(KIM-1 intraindividual SD: 0.16 ng/mg Cr, 95% CI: 
0.12–0.22 ng/mg Cr; NGAL intraindividual SD: 
3.84 ng/mg Cr; 95% CI: 2.57–5.74 ng/mg Cr). Diur-
nal effects were assessed using paired urine samples col-
lected in the evening and the following morning in the 
UK cohort. For KIM-1 (n = 35) there was a significant 
diurnal variation (p < 0.001) with lower mean concen-
tration in the evening (0.47 ng/mg Cr; 95% CI: 0.36–
0.62 ng/mg Cr) compared with the morning (0.77 ng/
mg Cr, 95% CI: 0.61–0.97 ng/mg Cr). No diurnal 
effect was seen for NGAL (n = 36; mean evening con-
centration: 7.35 ng/mg Cr, 95% CI: 4.96–10.89 ng/
mg Cr; mean morning concentration: 6.77 ng/mg Cr, 
95% CI: 4.85–9.46 ng/mg Cr; p = 0.36).
Reference intervals for urinary creatinine were 
calculated as above utilizing a quantile regression 
approach, and are given in Table 3. Both the 2.5th and 
97.5th quantiles show a significant increase with age. 
Differences between the MSD and Luminex meth-
ods of biomarker ana lysis were assessed. For both 
markers there was an increase in the difference in 
biomarker value as the magnitude of the measurement 
increased. A regression model was used, first to regress 
the difference between the methods on the average of 
the two methods, and then to regress the values of the 
residuals (Figure 1). Using this approach, the differ-
ence (D[KIM-1], pg/ml) between the two methods 
for KIM-1 (Luminex minus MSD) is described by the 
equation D[KIM-1] = -105.23 + 1.3124*A[KIM-1], 
where A[KIM-1] is the mean of the two methods (in 
pg/ml). 95% limits of agreement are given by the equa-
tion D[KIM-1] ± 1.96*216.7. The difference (D[N-
GAL], pg/ml) between the two methods for NGAL 
(Luminex minus MSD) is described by the equation 
D[NGAL] = -12.894 + 1.2006*A[NGAL], where 
A[NGAL] is the mean of the two methods (in pg/ml). 
95% limits of agreement are given by the equation 
D[NGAL] ± 1.96*65.44.
Discussion
The International Federation of Clinical Chemistry 
(IFCC) [19] recommends that samples from 120 or more 
individuals are required for the development of reference 
intervals for analytes. In this study we were able to meet 
this figure, although larger numbers would improve the 
confidence of the reference intervals we have derived 
(recommended CI:RI ratio is less than 0.2) [13]. We felt 
it was important to present reference intervals by parti-
tions, where they are significant, in order to give a true 
picture of our data. However, partitioning the group 
by sex or ethnicity leads to a loss of confidence, and, in 
some cases, to very wide confidence intervals. This is 
a limitation of our study, but was a necessary balance 
against the difficulty, length of time and investment 
that would be required for a much larger study. While 
we set out to recruit from birth to 16 years of age in the 
UK cohort, in practice only one child under 1 year of 
age was successfully recruited, and we have therefore 
presented reference intervals for children aged 1 year 
and above. Another study will be required to develop 
useful reference intervals for neonates/infants that take 
into account the rapid maturation and changes in renal 
function that occur during this period. We normalized 
biomarker values to urinary creatinine, but urinary cre-
atinine concentration itself demonstrates age-related 
changes (Table 3) [20,21], and there is ongoing debate as 
to the most appropriate standard [22].
In both cohorts, there was a significantly higher 
mean NGAL concentration in females compared with 
males. This gender difference has also been observed 
in adults [23], children [24] and in very low birth weight 
infants [25,26], although the reasons for the difference 
remain unclear. One recent study in children, using a 
different NGAL assay, did not demonstrate this gen-
der difference, although the NGAL values they report 
are similar to those we found with the MSD assay [27]. 
We found that for both biomarkers concentration was 
related to age, as has been previously reported [24]. 
Table 2. Biomarker reference intervals by quantile regression (cont.). 
Cohort and 
biomarker
2.5th quantile (90% CI), 
ng/mg Cr
50th quantile (90% CI), 
ng/mg Cr
97.5th quantile (90% CI), 
ng/mg Cr
CI:RI 
ratio
US NGAL (MSD), males (n = 90)
Age 7–8 years 1.34 (0–1.50) 3.10 (2.55–3.77) 8.28 (6.34–10.81) 0.64
Age 9–12 years 1.34 (0–1.50) 4.23 (3.63–4.95) 10.38 (8.83–12.20) 0.37
Age 13–16 years 1.34 (0–1.50) 6.42 (4.56–9.03) 14.02 (10.67–18.42) 0.61
95% RIs (2.5th and 97.5th quantiles) along with median values (50th quantile) and their 90% CIs were estimated using quantile regression 
methodology. RIs are reported by cohort (UK or USA), biomarker (KIM‑1 or NGAL) and analytical method (MSD or Luminex). Where 
biomarker concentrations were significantly associated with sex or ethnicity (p < 0.05), RIs are presented by these partitions. We report 
quantile values for the middle age within each age group. A ratio of the 90% CI for the 97.5th quantile to the 95% RI (CI:RI ratio) is given. 
The US Cohort contained children aged 7–16 years only.  
†For RIs where there was no significant association with age, it was not possible to calculate upper limits for the CIs due to small sample size 
and the extreme percentile. 
CI: Confidence interval; Cr: Creatinine; Inf: Infinity; MSD: Meso Scale Discovery; RI: Reference interval.
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However, age-related changes were not consistent for 
each biomarker across both cohorts and analytical plat-
forms, and these results must be interpreted with cau-
tion. Significant differences in mean values of KIM-1 
were observed between the two cohorts. Factors con-
tributing to this difference may be ethnicity and the 
time of day of sample collection, as we have shown, for 
the first time, diurnal variation in KIM-1 concentration 
with lower values in the evening. The reference inter-
vals for the UK cohort are based on samples collected 
in the morning, whereas the US samples were collected 
at varying times of day. Furthermore, urine samples for 
the UK study were spot collections, whereas in the US 
cohort they were 4-h collections, although it is unclear 
whether this would make a  difference.
An important aspect for the rolling qualification of 
novel urinary biomarkers and for their eventual use in 
man is that independent and robust methodologies are 
developed for their quantification. KIM-1 and NGAL 
have primarily been quantified in man via Luminex-
based technologies. In the UK cohort we compared this 
method to a MSD-based method for the quantification 
of both KIM-1 and NGAL. Although absolute differ-
ences in biomarker values were observed, due to differ-
ences in the antibodies used and their affinities for the 
biomarker of interest, there remained strong agreement 
between both analytical platforms.
Conclusion & future perspective
We have reported reference intervals for two urinary 
renal injury biomarkers, KIM-1 and NGAL, for the 
first time in two independent healthy pediatric popula-
tions, and have shown that they can be robustly quan-
tified on two independent analytical platforms with a 
high degree of agreement. This represents a key step 
in the qualification of these two biomarkers for use in 
children. A number of groups are currently working on 
identifying clinical scenarios in which these biomarkers 
hold diagnostic or prognostic advantages over tradi-
tional measures of kidney injury. A key strength over 
traditional markers lies in their specificity for damage 
to certain portions of the kidney nephron. This may 
be particularly advantageous in the early identification 
of drug-induced kidney injury, which commonly starts 
with localized injury. While these novel biomarkers 
may have increased sensitivity and specificity when 
Table 3. Reference intervals of urinary creatinine (n = 106).
Reference interval 2.5th quantile (90% CI), 
ng/mg Cr
50th quantile (90% CI), 
ng/mg Cr
97.5th quantile (90% CI), 
ng/mg Cr
CI:RI 
ratio
Urinary Cr (mg/ml)
Age 1–4 years 0.47 (0.19–0.74) 0.71 (0.54–0.93) 1.59 (1.21–2.09) 0.78
Age 5–8 years 0.69 (0.53–0.86) 0.97 (0.81–1.16) 2.00 (1.70–2.36) 0.51
Age 9–12 years 0.92 (0.80–1.04) 1.32 (1.12–1.56) 2.52 (2.24–2.84) 0.38
Age 13–16 years 1.15 (0.97–1.34) 1.80 (1.41–2.31) 3.17 (2.63–3.81) 0.59
95% RIs along with median values and their 90% CIs for urinary creatinine in the UK cohort were derived using quantile regression 
methodology. 
CI: Confidence interval; Cr: Creatinine; RI: Reference interval.
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Figure 1. Agreement of Meso Scale Discovery and Luminex methods for ana lysis of urinary KIM‑1 and NGAL. 
(A) KIM‑1; (B) NGAL. Regression models describing the differences between the Luminex and MSD methods 
of biomarker ana lysis. The regression line is given using a solid line, and the upper and lower 95% limits of 
agreement with dashed lines. 
MSD: Meso Scale Discovery. 
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compared with traditional measures of AKI, in order 
to provide clinical benefit these diagnostic tools need to 
be followed by improved interventions, leading to bet-
ter patient outcomes. Earlier diagnosis may allow ear-
lier interventions, and future studies will need to assess 
whether interventions made on the basis of changes in 
novel biomarkers lead to improved outcomes. It will only 
be when this link is established that novel biomarkers 
will become routinely used in clinical practice.
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Executive summary
Background
•	 There is increasing interest in a number of novel urinary biomarkers that are not only more sensitive than 
serum creatinine for the identification of acute kidney injury, but can also indicate the site of damage to 
different portions of the nephron. 
•	 The aim of this study was to describe reference intervals in healthy children for two of these biomarkers, 
urinary KIM‑1 and NGAL.
Methods
•	 Reference intervals were defined in cohorts of healthy children in the UK (n = 120) and the USA (n = 171).
Results
•	 Concentrations of urinary KIM‑1 varied with age and with ethnicity, and showed diurnal variation, with higher 
concentrations in the morning.
•	 In both cohorts, there was a significantly higher mean NGAL concentration in females compared with males. 
NGAL concentration also varied with age.
•	 We compared the Meso Scale Discovery (MSD) and Luminex methods of biomarker ana lysis. Although 
absolute differences in biomarker values were observed, there was strong agreement between both analytical 
platforms.
Conclusion
•	 The definition of healthy pediatric reference intervals is an important step in the qualification of KIM‑1 and 
NGAL for use in children to identify acute kidney injury.
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